Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of August 2003. The report serves to incorporate by reference a Proxy Statement for a Special General Meeting of Shareholders scheduled for September 8, 2003. The primary purpose of the meeting is to seek shareholder approval for the purchase of a Directors and Officers (D&O) Insurance Policy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and insurance procurement rather than financial performance.
- Outstanding Ordinary Shares: 26,371,709 (as of August 12, 2003).
- D&O Insurance Coverage: $10,000,000 total coverage.
- D&O Insurance Premium: $305,000 annual premium for the year beginning August 9, 2003.
Material Changes
No material changes to financial operations or business strategy are reported in this filing. The document details a procedural change regarding the authorization of D&O insurance premiums for future years, allowing increases of up to 15% per annum without further shareholder approval, subject to Board and Audit Committee consent.
Guidance, Outlook, and Risks
Management Commentary: The Board of Directors expresses no recommendation regarding the vote on the D&O insurance proposal, as required by Israeli law for matters relating to director compensation. Management is not aware of any other matters to be presented at the meeting.
Risks and Contingencies: The filing notes that if a quorum (33 1/3% of outstanding shares) is not present within one hour of the meeting start time, the meeting will be adjourned to September 15, 2003. At an adjourned meeting, any two shareholders present constitute a quorum.
Important Facts for Investors to Verify
- Shareholder approval is required under Israeli law for the $305,000 annual D&O insurance premium.
- Major shareholders as of August 12, 2003, include Clal Biotechnology Industries Ltd. (11.54%), Martin S. Gerstel (6.33%), and Apax (OCS) Nominees Limited (5.17%).
- The Board has authorized future D&O insurance renewals with premiums increasing by no more than 15% annually without additional shareholder votes.
- The filing contains no financial performance data; investors should refer to the most recent Form 20-F for revenue and earnings information.